Bicara Therapeutics (BCAX) on Friday filed a registration statement with the US Securities and Exchange Commission to issue up to $400 million of securities.
The filing also includes a sales-agreement prospectus to sell up to $150 million of common stock under an at-the-market arrangement with TD Securities, the company said.